Trials / Terminated
TerminatedNCT04458259
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07265807 | Given 2 weeks on/1 week off |
| DRUG | Sasanlimab | Given SC Q3W |
| DRUG | Axitinib | Dosed per package label starting with 5 mg PO BID |
Timeline
- Start date
- 2020-09-24
- Primary completion
- 2024-11-15
- Completion
- 2024-11-15
- First posted
- 2020-07-07
- Last updated
- 2025-08-28
Locations
33 sites across 5 countries: United States, Canada, Italy, Japan, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04458259. Inclusion in this directory is not an endorsement.